LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Publisher: W.B. Saunders
Languages: English
Types: Article
Subjects: RD, RC0254
Although there is increasing appreciation of the role of the host inflammatory response in determining outcome in patients in colorectal cancer, there has been little concerted effort to favourably manipulate cancer-associated inflammation, either alone or in combination with current oncological treatment. Epidemiological and cardiovascular disease studies have identified aspirin, other nonsteroidal anti-inflammatory drugs and statins as potential chemotherapeutic agents which may manipulate the host inflammatory response to the benefit of the patient with cancer. Similarly, evidence of a chemotherapeutic effect of histamine-2 receptor antagonists, again mediated by an immunomodulatory effect, has previously led to increased interest in their use in gastrointestinal cancer. Extensive pre-clinical data and a limited number of clinical investigations have proposed a direct effect of these agents on tumour biology, with an anti-tumour effect on several of the hallmarks of cancer, including proliferative capacity, evasion from apoptosis and cell cycle regulation, and invasive capability of tumour cells. Furthermore, clinical evidence has suggested a pertinent role in down-regulating the systemic inflammatory response whilst favourably influencing the local inflammatory response within the tumour microenvironment. Despite such compelling results, the clinical applicability of nonsteroidal anti-inflammatory drugs, statins and histamine-2 receptor antagonists has not been fully realised, particularly in patients identified at high risk on the basis of inflammatory parameters. In the present review, we examine the potential role that these agents may play in improving survival and reducing recurrence in patients with potentially curative colorectal cancer, and in particular focus on their effects on the local and systemic inflammatory response.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. UK CR. Bowel cancer statistics: Cancer Research UK. Available from: http://info.cancerresearchuk.org/cancerstats/types/bowel/mortality.
    • 2. McArdle CS, McMillan DC, Hole DJ. Male gender adversely affects survival following surgery for colorectal cancer. Br J Surg. 2003 Jun;90(6):711-5.
    • 3. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009 Jul 1;27(19):3109-16.
    • 4. Ali R, Toh HC, Chia WK. The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial. Trials. 2011;12:261.
    • 5. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009 Jul 30;30(7):1073-81.
    • 6. Roxburgh CSD, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev. 2012 Aug;38(5):451-66.
    • 7. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncology. 2010 Feb;6(1):149-63.
    • 8. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999 Feb;340(6):448-54.
    • 9. Lin CY, Bai DJ, Yuan HY, Wang K, Yang GL, Hu MB, et al. Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial. World J Gastroenterol. 2004 Jan;10(1):136-42.
    • 10. Ueda T, Shimada E, Urakawa T. Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol. 1994 Aug;29(4):423-9.
    • 11. Hanna N, Fidler IJ. Role of natural killer cells in the destruction of circulating tumor emboli. J Natl Cancer Inst. 1980 Oct;65(4):801-9.
    • 12. McMillan DC, Fyffe GD, Wotherspoon HA, Cooke TG, McArdle CS. Prospective study of circulating T-lymphocyte subpopulations and disease progression in colorectal cancer. Dis Colon Rectum. 1997 Sep;40(9):1068-71.
    • 13. Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer-reinterpreting paradigms. Nat Rev Clin Oncol. 2012 Aug 21;9(10):561-70.
    • 14. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994 Aug 15;121(4):241-6.
    • 15. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995 Sep 7;333(10):609-14.
    • 16. Benedetti AL, Collet JP, Boivin JF, Hanley JA. Effect of nonsteroidal anti-inflammatory drugs on stage of colon cancer at diagnosis. J Clin Epidemiol. 2003 Aug;56(8):782-7.
    • 17. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012 Apr 28;379(9826):1591-601.
    • 18. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007 May 12;369(9573):1603-13.
    • 19. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010 Nov 20;376(9754):1741-50.
    • 20. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW, Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993 Mar 15;53(6):1322-7.
    • 21. Thun MJM, Namboodiri MMM, Heath CWC. Aspirin use and reduced risk of fatal colon cancer. The New England journal of medicine. 1991 Dec 05;325(23):1593-6.
    • 22. Zell JA, Ziogas A, Bernstein L, Clarke CA, Deapen D, Largent JA, et al. Nonsteroidal antiinflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer. 2009 Dec 15;115(24):5662-71.
    • 23. Coghill AE, Newcomb PA, Campbell PT, Burnett-Hartman AN, Adams SV, Poole EM, et al. Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer. Gut. 2011 Apr;60(4):491-8.
    • 24. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2007 Mar 6;146(5):361-4.
    • 25. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74.
    • 26. Giardiello FMF, Hamilton SRS, Krush AJA, Piantadosi SS, Hylind LML, Celano PP, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. The New England journal of medicine. 1993 Jun 05;328(18):1313-6.
    • 27. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011 Dec 17;378(9809):2081-7.
    • 28. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology. 2007 Aug;133(2):393-402.
    • 29. Harris RE, Beebe-Donk J, Alshafie GA. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer. 2008;8:237.
    • 30. Church RD, Fleshman JW, McLeod HL. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg. 2003 Sep;90(9):1055-67.
    • 31. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med. 2007;58:239-52.
    • 32. Fenwick SW, Toogood GJ, Lodge JP, Hull MA. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology. 2003 Sep;125(3):716-29.
    • 33. Chalmers CR, Wilson DJ, Ward J, Robinson PJ, Toogood GJ, Hull MA. Antiangiogenic activity of the selective cyclooxygenase 2 inhibitor rofecoxib in human colorectal cancer liver metastases. Gut. 2006 Jul;55(7):1058-9.
    • 34. Auman JT, Church R, Lee SY, Watson MA, Fleshman JW, McLeod HL. Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer. 2008 Aug;44(12):1754-60.
    • 35. Lonnroth C, Andersson M, Nordgren S, Lundholm K. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment. Int J Oncol. 2012 Jul;41(1):15-23.
    • 36. Tuynman JB, Peppelenbosch MP, Richel DJ. COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit Rev Oncol Hematol. 2004 Nov;52(2):81-101.
    • 37. Schror K. Pharmacology and cellular/molecular mechanisms of action of aspirin and nonaspirin NSAIDs in colorectal cancer. Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):473-84.
    • 38. Dimberg J, Samuelsson A, Hugander A, Soderkvist P. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut. 1999 Nov;45(5):730-2.
    • 39. Nasir A, Kaiser HE, Boulware D, Hakam A, Zhao H, Yeatman T, et al. Cyclooxygenase-2 expression in right- and left-sided colon cancer: a rationale for optimization of cyclooxygenase-2 inhibitor therapy. Clin Colorectal Cancer. 2004 Feb;3(4):243-7.
    • 40. Gustafsson A, Hansson E, Kressner U, Nordgren S, Andersson M, Wang W, et al. EP1-4 subtype, COX and PPAR gamma receptor expression in colorectal cancer in prediction of diseasespecific mortality. Int J Cancer. 2007 Jul 15;121(2):232-40.
    • 41. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007 May 24;356(21):2131-42.
    • 42. Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ, et al. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2726-33.
    • 43. Krishnan K, Ruffin MT, Normolle D, Shureiqi I, Burney K, Bailey J, et al. Colonic mucosal prostaglandin E2 and cyclooxygenase expression before and after low aspirin doses in subjects at high risk or at normal risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):447- 53.
    • 44. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol. 2012 May;9(5):259-67.
    • 45. Sciulli MG, Filabozzi P, Tacconelli S, Padovano R, Ricciotti E, Capone ML, et al. Platelet activation in patients with colorectal cancer. Prostaglandins Leukot Essent Fatty Acids. 2005 Feb;72(2):79-83.
    • 46. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst. 2006 Jun 7;98(11):736-47.
    • 47. Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der Neut R, et al. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer. 2004 Jan 12;90(1):224-9.
    • 48. Greenspan EJ, Madigan JP, Boardman LA, Rosenberg DW. Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev Res (Phila). 2011 Jan;4(1):161-71.
    • 49. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012 Oct 25;367(17):1596-606.
    • 50. Seufert BL, Poole EM, Whitton J, Xiao L, Makar KW, Campbell PT, et al. IkappaBKbeta and NFkappaB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry. Carcinogenesis. 2013 Jan;34(1):79-85.
    • 51. Solheim TS, Fearon KC, Blum D, Kaasa S. Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol. 2013 Jan;52(1):6-17.
    • 52. Chan AT, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology. 2011 Mar;140(3):799-808, quiz e11.
    • 53. Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila). 2011 Aug;4(8):1172-80.
    • 54. Hussain M, Javeed A, Ashraf M, Al-Zaubai N, Stewart A, Mukhtar MM. Non-steroidal antiinflammatory drugs, tumour immunity and immunotherapy. Pharmacol Res. 2012 Jul;66(1):7-18.
    • 55. Lonnroth C, Andersson M, Arvidsson A, Nordgren S, Brevinge H, Lagerstedt K, et al. Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun. 2008;8:5.
    • 56. Yaqub S, Henjum K, Mahic M, Jahnsen FL, Aandahl EM, Bjornbeth BA, et al. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner. Cancer Immunol Immunother. 2008 Jun;57(6):813-21.
    • 57. Han T, Nemoto T, Ledesma EJ, Bruno S. Enhancement of T lymphocyte proliferative response to mitogens by indomethacin in breast and colorectal cancer patients. Int J Immunopharmacol. 1983;5(1):11-5.
    • 58. Balch CM, Dougherty PA, Cloud GA, Tilden AB. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery. 1984 Jan;95(1):71-7.
    • 59. Markewitz A, Faist E, Lang S, Endres S, Fuchs D, Reichart B. Successful restoration of cellmediated immune response after cardiopulmonary bypass by immunomodulation. J Thorac Cardiovasc Surg. 1993 Jan;105(1):15-24.
    • 60. Gogos CA, Maroulis J, Zoumbos NC, Salsa B, Kalfarentzos F. Effect of Parenteral Indomethacin on T-Lymphocyte Subpopulations and Cytokine Production in Patients under Major Surgical Operations. Res Exp Med (Berl). 1995 Apr;195(2):85-92.
    • 61. Ho GY, Xue X, Cushman M, McKeown-Eyssen G, Sandler RS, Ahnen DJ, et al. Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas. J Natl Cancer Inst. 2009 Dec 2;101(23):1650-4.
    • 62. Konturek PC, Rembiasz K, Burnat G, Konturek SJ, Tusinela M, Bielanski W, et al. Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. Dig Dis Sci. 2006 Apr;51(4):779-87.
    • 63. McMillan DC, Leen E, Smith J, Sturgeon C, Preston T, Cooke TG, et al. Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol. 1995 Oct;21(5):531-4.
    • 64. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009 Aug 12;302(6):649-58.
    • 65. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, et al. Use of aspirin postdiagnosis improves survival for colon cancer patients. Br J Cancer. 2012 Apr 24;106(9):1564-70.
    • 66. Fuchs CS, Meyerhardt JA, Heseltine DL, Niedzwiecki D, Hollis D, Chan AT, et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. J Clin Oncol. 2005 2005;23(16S):3530.
    • 67. Midgley RS, McConkey CC, Johnstone EC, Dunn JA, Smith JL, Grumett SA, et al. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol. 2010 Oct 20;28(30):4575-80.
    • 68. Phase III Randomized Study of Adjuvant Celecoxib With Fluorouracil and Leucovorin Calcium in Patients With Curatively Resected Stage III Adenocarcinoma of the Colon National Cancer Institute: National Institutes of Health; 2004 [updated 22/6/2006; cited 2012 October]. Available from: http://cancer.gov/clinicaltrials/search/view?cdrid=367335&version=healthprofession al.
    • 69. Davis TW, Hunter N, Trifan OC, Milas L, Masferrer JL. COX-2 inhibitors as radiosensitizing agents for cancer therapy. Am J Clin Oncol. 2003 Aug;26(4):S58-61.
    • 70. Debucquoy A, Roels S, Goethals L, Libbrecht L, Van Cutsem E, Geboes K, et al. Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer. Radiother Oncol. 2009 Nov;93(2):273-8.
    • 71. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist. 2006 Mar;11(3):306-15.
    • 72. Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut. 2010 Nov;59(11):1572-85.
    • 73. Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005 May 26;352(21):2184-92.
    • 74. Hachem C, Morgan R, Johnson M, Kuebeler M, El-Serag H. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am J Gastroenterol. 2009 May;104(5):1241-8.
    • 75. Lakha F, Theodoratou E, Farrington SM, Tenesa A, Cetnarskyj R, Din FV, et al. Statin use and association with colorectal cancer survival and risk: case control study with prescription data linkage. BMC Cancer. 2012 Oct 22;12(1):487.
    • 76. Bonovas S, Filioussi K, Flordellis CS, Sitaras NM. Statins and the risk of colorectal cancer: a meta-analysis of 18 studies involving more than 1.5 million patients. J Clin Oncol. 2007 Aug 10;25(23):3462-8.
    • 77. Notarnicola M, Messa C, Pricci M, Guerra V, Altomare DF, Montemurro S, et al. Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer. Anticancer Res. 2004 Nov-Dec;24(6):3837-42.
    • 78. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res. 1999 Aug;5(8):2223-9.
    • 79. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003 Oct;4(4):257-62.
    • 80. Wachtershauser A, Akoglu B, Stein J. HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis. 2001 Jul;22(7):1061-7.
    • 81. Qi XF, Kim DH, Yoon YS, Kim SK, Cai DQ, Teng YC, et al. Involvement of oxidative stress in simvastatin-induced apoptosis of murine CT26 colon carcinoma cells. Toxicol Lett. 2010 Dec 15;199(3):277-87.
    • 82. Skaletz-Rorowski A, Walsh K. Statin therapy and angiogenesis. Curr Opin Lipidol. 2003 Dec;14(6):599-603.
    • 83. Hinoue T, Weisenberger DJ, Pan F, Campan M, Kim M, Young J, et al. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. PLoS One. 2009;4(12):e8357.
    • 84. Kodach LL, Jacobs RJ, Voorneveld PW, Wildenberg ME, Verspaget HW, van Wezel T, et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut. 2011 Nov;60(11):1544-53.
    • 85. Wang W, Collie-Duguid E, Cassidy J. Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett. 2002 Nov 20;531(3):415-20.
    • 86. Riganti C, Doublier S, Costamagna C, Aldieri E, Pescarmona G, Ghigo D, et al. Activation of nuclear factor-kappa B pathway by simvastatin and RhoA silencing increases doxorubicin cytotoxicity in human colon cancer HT29 cells. Mol Pharmacol. 2008 Aug;74(2):476-84.
    • 87. Lee J, Lee I, Han B, Park JO, Jang J, Park C, et al. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst. 2011 Apr 20;103(8):674-88.
    • 88. Katz MS, Minsky BD, Saltz LB, Riedel E, Chessin DB, Guillem JG. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1363-70.
    • 89. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005 Dec;4(12):977-87.
    • 90. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000 Dec;6(12):1399-402.
    • 91. Samadder NJ, Mukherjee B, Huang SC, Ahn J, Rennert HS, Greenson JK, et al. Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer. 2011 Apr 15;117(8):1640-8.
    • 92. Lee JY, Kim JS, Kim JM, Kim N, Jung HC, Song IS. Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol. 2007 Feb;7(2):241-8.
    • 93. Cho SJ, Kim JS, Kim JM, Lee JY, Jung HC, Song IS. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. Int J Cancer. 2008 Aug 15;123(4):951-7.
    • 94. Suh N, Reddy BS, DeCastro A, Paul S, Lee HJ, Smolarek AK, et al. Combination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/betacatenin/cyclin D1 signaling pathway in rats. Cancer Prev Res (Phila). 2011 Nov;4(11):1895-902.
    • 95. Banez LL, Klink JC, Jayachandran J, Lark AL, Gerber L, Hamilton RJ, et al. Association between statins and prostate tumor inflammatory infiltrate in men undergoing radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):722-8.
    • 96. Malicki S, Winiarski M, Matlok M, Kostarczyk W, Guzdek A, Konturek PC. IL-6 and IL-8 responses of colorectal cancer in vivo and in vitro cancer cells subjected to simvastatin. J Physiol Pharmacol. 2009 Dec;60(4):141-6.
    • 97. Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, et al. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun. 2012 Jul;26(5):699-705.
    • 98. Coogan PF, Smith J, Rosenberg L. Statin use and risk of colorectal cancer. J Natl Cancer Inst. 2007 Jan 3;99(1):32-40.
    • 99. Siddiqui AA, Nazario H, Mahgoub A, Patel M, Cipher D, Spechler SJ. For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Dig Dis Sci. 2009 Jun;54(6):1307-11.
    • 100. Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, et al. Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011 Oct 19;103(20):1540-51.
    • 101. Lipkin SM, Chao EC, Moreno V, Rozek LS, Rennert H, Pinchev M, et al. Genetic variation in 3- hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila). 2010 May;3(5):597-603.
    • 102. Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery 2009 [updated 09/02/2012; cited 2012 05/12/2012]. Available from: http://clinicaltrials.gov/show/NCT01011478.
    • 103. Tønnesen H, Knigge U, Bülow S, Damm P, Fischerman K, Hesselfeldt P, et al. Effect of cimetidine on survival after gastric cancer. Lancet. 1988 Oct;2(8618):990-2.
    • 104. Harvey VJ, Slevin ML, Dilloway MR, Clark PI, Johnston A, Lant AF. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol. 1984 Sep;18(3):421-30.
    • 105. Adams WJ, Lawson JA, Morris DL. Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. Gut. 1994 Nov;35(11):1632-6.
    • 106. Cianchi F, Cortesini C, Schiavone N, Perna F, Magnelli L, Fanti E, et al. The role of cyclooxygenase-2 in mediating the effects of histamine on cell proliferation and vascular endothelial growth factor production in colorectal cancer. Clin Cancer Res. 2005 Oct;11(19 Pt 1):6807-15.
    • 107. Masini E, Fabbroni V, Giannini L, Vannacci A, Messerini L, Perna F, et al. Histamine and histidine decarboxylase up-regulation in colorectal cancer: correlation with tumor stage. Inflamm Res. 2005 Apr;54 Suppl 1:S80-1.
    • 108. Boer K, Helinger E, Helinger A, Pocza P, Pos Z, Demeter P, et al. Decreased expression of histamine H1 and H4 receptors suggests disturbance of local regulation in human colorectal tumours by histamine. Eur J Cell Biol. 2008 Apr;87(4):227-36.
    • 109. Chen JS, Lin SY, Tso WL, Yeh GC, Lee WS, Tseng H, et al. Checkpoint kinase 1-mediated phosphorylation of Cdc25C and bad proteins are involved in antitumor effects of loratadine-induced G2/M phase cell-cycle arrest and apoptosis. Mol Carcinog. 2006 Jul;45(7):461-78.
    • 110. Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer. 2002 Jan;86(2):161-7.
    • 111. Siegel JN, Schwartz A, Askenase PW, Gershon RK. T-cell suppression and contrasuppression induced by histamine H2 and H1 receptor agonists, respectively. Proc Natl Acad Sci U S A. 1982 Aug;79(16):5052-6.
    • 112. Adams WJ, Morris DL. Short-course cimetidine and survival with colorectal cancer. Lancet. 1994 1994 Dec 24-31;344(8939-8940):1768-9.
    • 113. Adams WJ, Morris DL. Pilot study--cimetidine enhances lymphocyte infiltration of human colorectal carcinoma: results of a small randomized control trial. Cancer. 1997 Jul 1;80(1):15-21.
    • 114. Kelly MD, King J, Cherian M, Dwerryhouse SJ, Finlay IG, Adams WJ, et al. Randomized trial of preoperative cimetidine in patients with colorectal carcinoma with quantitative assessment of tumorassociated lymphocytes. Cancer. 1999 Apr;85(8):1658-63.
    • 115. Kapoor S, Pal S, Sahni P, Dattagupta S, Kanti Chattopadhyay T. Effect of pre-operative short course famotidine on tumor infiltrating lymphocytes in colorectal cancer: a double blind, placebo controlled, prospective randomized study. J Surg Res. 2005 Dec;129(2):172-5.
    • 116. Nielsen HJ, Moesgaard F, Hammer JH. Effect of ranitidine and low-dose interleukin-2 in vitro on NK-cell activity in peripheral blood from patients with liver metastases from colorectal cancer. Eur J Surg Oncol. 1995 Oct;21(5):526-30.
    • 117. Adams WJ, Morris DL, Ross WB, Lubowski DZ, King DW, Peters L. Cimetidine preserves nonspecific immune function after colonic resection for cancer. Aust N Z J Surg. 1994 Dec;64(12):847-52.
    • 118. Rasmussen LA, Nielsen HJ, Sorensen S, Sorensen C, Rasmussen R, Moesgaard F, et al. Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis. J Am Coll Surg. 1995 Aug;181(2):138-44.
    • 119. Matsumoto S. Cimetidine and survival with colorectal cancer. Lancet. 1995 Jul;346(8967):115.
    • 120. Svendsen LB, Ross C, Knigge U, Frederiksen HJ, Graversen P, Kjaergård J, et al. Cimetidine as an adjuvant treatment in colorectal cancer. A double-blind, randomized pilot study. Dis Colon Rectum. 1995 May;38(5):514-8.
    • 121. Nielsen HJ, Christensen IJ, Moesgaard F, Kehlet H, Group DRCCS. Ranitidine as adjuvant treatment in colorectal cancer. Br J Surg. 2002 Nov;89(11):1416-22.
    • 122. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010 Jun;138(6):2073-87 e3.
    • 123. Deva S, Jameson M. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane Database Syst Rev. 2012;8:CD007814.
    • 124. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012;10:205.
  • No related research data.
  • No similar publications.

Share - Bookmark

Download from

Cite this article